The latest price target for Immix Biopharma (NASDAQ: IMMX) was reported by Roth MKM on February 22, 2023. The analyst firm set a price target for $14.00 expecting IMMX to rise to within 12 months (a possible 566.67% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Immix Biopharma (NASDAQ: IMMX) was provided by Roth MKM, and Immix Biopharma initiated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immix Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immix Biopharma was filed on February 22, 2023 so you should expect the next rating to be made available sometime around February 22, 2024.

While ratings are subjective and will change, the latest Immix Biopharma (IMMX) rating was a initiated with a price target of $0.00 to $14.00. The current price Immix Biopharma (IMMX) is trading at is $2.10, which is within the analyst's predicted range.